TY - JOUR KW - Soil-transmitted helminths KW - Mass drug administration KW - Access to treatment AU - Lo N AU - Andrews JR AU - Bogoch I AB -

Soil-transmitted helminths affect about 1·5 billion people living in the world's poorest regions. The main public health strategy for morbidity control is mass drug administration (MDA; also referred to as preventive chemotherapy), which is the widespread empirical treatment of populations, traditionally school-aged children. WHO set a goal of achieving 75% coverage of at-risk populations by 2020, but estimates from 2014 suggest only 47% global coverage of children. To reach the WHO 2020 goal, opportunities must be taken to find cost efficiencies, collaborate across health sectors, and improve measurement of the costs and effects of MDA programmes. The substantial gap in target coverage for treatment of soil-transmitted helminths poses a great challenge, but an even greater opportunity to address the global burden from these infections.

BT - The Lancet. Infectious diseases DO - 10.1016/S1473-3099(16)30049-4 IS - 7 J2 - The Lancet Infectious Diseases LA - eng N2 -

Soil-transmitted helminths affect about 1·5 billion people living in the world's poorest regions. The main public health strategy for morbidity control is mass drug administration (MDA; also referred to as preventive chemotherapy), which is the widespread empirical treatment of populations, traditionally school-aged children. WHO set a goal of achieving 75% coverage of at-risk populations by 2020, but estimates from 2014 suggest only 47% global coverage of children. To reach the WHO 2020 goal, opportunities must be taken to find cost efficiencies, collaborate across health sectors, and improve measurement of the costs and effects of MDA programmes. The substantial gap in target coverage for treatment of soil-transmitted helminths poses a great challenge, but an even greater opportunity to address the global burden from these infections.

PY - 2016 SP - 762 EP - 764 T2 - The Lancet. Infectious diseases TI - Improving helminth treatment access: costs and opportunities. UR - http://ac.els-cdn.com/S1473309916300494/1-s2.0-S1473309916300494-main.pdf?_tid=99ee20cc-3e0a-11e6-9f5e-00000aacb35e&acdnat=1467212773_1d3dd58a5bbf57e9392b6f2e9f32e22a VL - 16 SN - 14733099 ER -